Any adverse event · adults (age 18 years and older) with EGPA ANCA‐associated vasculitis
Mepolizumab showed no clear difference in any adverse event compared with placebo (low certainty).
1 finding from 1 review
RR 1.03 [0.96, 1.11]
Studies not reported
Low
Any serious adverse event · adults (age 18 years and older) with EGPA ANCA‐associated vasculitis
Mepolizumab showed no clear difference in any serious adverse event compared with placebo (low certainty).
1 finding from 1 review
RR 0.67 [0.35, 1.28]
Studies not reported
Low
Withdrawals due to adverse events · adults (age 18 years and older) with EGPA ANCA‐associated vasculitis
Mepolizumab showed no clear difference in any withdrawals due to AEs compared with placebo (low certainty).
1 finding from 1 review
RR 2 [0.19, 21.54]
Studies not reported
Low
MortalityNumber of participants: 285(2 RCTs) WGET 2005 · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in mortalityNumber of participants: 285(2 RCTs) WGET 2005 compared with standard therapy with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Treatment failure day‐28 PCR‐adjusted(PP population) · children aged 14 years or younger with uncomplicated P falciparum malaria
The intervention showed no clear difference in treatment failure day‐28 PCR‐adjusted(PP population) (low certainty).
1 finding from 1 review
Intervention not reported
Treatment failureday‐28 PCR‐adjusted(ITT population) · children aged 14 years or younger with uncomplicated P falciparum malaria
The intervention showed no clear difference in treatment failureday‐28 PCR‐adjusted(ITT population) (low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · children aged 14 years or younger with uncomplicated P falciparum malaria
The intervention showed no clear difference in serious adverse events (low certainty).
1 finding from 1 review
Intervention not reported
Drug‐related adverse events · children aged 14 years or younger with uncomplicated P falciparum malaria
The intervention probably leads to lower drug‐related adverse events (moderate certainty).
1 finding from 1 review
Intervention not reported
Drug‐related vomiting · children aged 14 years or younger with uncomplicated P falciparum malaria
The intervention showed no clear difference in drug‐related vomiting (low certainty).
1 finding from 1 review
Intervention not reported
Acceptability · children aged 14 years or younger with uncomplicated P falciparum malaria
1 finding from 1 review
Disease‐specific quality of life · children with obstructive sleep‐disordered breathing
1 finding from 1 review
Peri‐operative blood loss (Volume measured in mL) · children with obstructive sleep‐disordered breathing
1 finding from 1 review
Postoperative complications requiring medical intervention (with or without hospitalisation) · children with obstructive sleep‐disordered breathing
Tonsillectomy probably leads to higher postoperative complications requiring medical intervention (with or… compared with tonsillotomy (moderate certainty).
1 finding from 1 review
Reduction in pain intensity · children with obstructive sleep‐disordered breathing
1 finding from 1 review
Return to normal activity · children with obstructive sleep‐disordered breathing
1 finding from 1 review
Recurrence of oSDB as a result of tonsil regrowth · children with obstructive sleep‐disordered breathing
It is very uncertain whether tonsillectomy changes recurrence of oSDB as a result of tonsil regrowth compared with tonsillotomy (very low certainty).
1 finding from 1 review
Reoperation rate · children with obstructive sleep‐disordered breathing
It is very uncertain whether tonsillectomy changes reoperation rates compared with tonsillotomy (very low certainty).
1 finding from 1 review
Intervention not reported
Side effects from intervention (as and when observed) Outcome measured up to day 56 ± 4 · people 60 years of age and older
1 finding from 1 review
Intervention not reported
Stratum corneum hydration (SCH) (at baseline and day 56 ± 4) Hahnel 2017: measured at 56 ± 4 days in mid‐volar arm and lower leg in arbitrary units from 0 (no water) to 120 (on water) using the Corneometer CM 825 Gillis 2016: measured at 12 weeks ... · people 60 years of age and older
1 finding from 1 review
Intervention not reported
Erythema · people 60 years of age and older
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found